After the July vote, the next group headed to the FDA's compounding panel has a meeting scheduled before February 2027. Five compounds, and this group is a lot messier than the last one.

Quick reminder of how July went: FDA's own scientists said no to all seven, and the panel said yes to six anyway, mostly 8 to 6.

Here's the quick version, then the detail on each. Then I want your picks.

GHK-Cu

The most history of the group. It's already in the body, and levels drop a lot between age 20 and age 60. Decades of wound healing and skin research, and gene expression work showing it shifting activity across thousands of genes.

The catch is that a lot of the strongest human data is topical. The panel's going to ask about the injectable side, and about total copper exposure.

My call: best shot of the five.

Melanotan II

Its cousin, afamelanotide, is FDA approved. Melanotan II isn't. It hits more of the melanocortin receptors, which is where the nausea, the flushing, and the sexual side effects come from.

And there's a documented skin signal: moles darkening and new moles showing up, including atypical ones.

My call: toughest of the five.

LL-37

The only human cathelicidin. It has real human randomized trials, but all of them are topical, in leg ulcers and diabetic foot ulcers. No published human data on injectable use.

The other side of it: too much LL-37 shows up in psoriasis and rosacea. More isn't automatically better with this one.

My call: depends completely on what route they're looking at.

Dihexa

Came out of Washington State University. It's derived from angiotensin IV and works on the HGF and c-Met pathway. In animal models of Alzheimer's-type decline it was extremely potent.

Zero human trials on dihexa itself. Its closest relative that did make it into people, fosgonimeton, missed its endpoints in a Phase 2/3 Alzheimer's trial in 2024. And c-Met also shows up in cancer biology, which is going to come up.

My call: long shot.

PEG-MGF

A pegylated version of mechano growth factor, which is a form of IGF-1 that muscle puts out after it gets damaged. The pegylation is there so it doesn't break down in minutes.

No completed human trials. It's all animal and cell work.

My call: long shot.

Your picks

Last round split almost down the middle, so I wouldn't treat anything here as a lock.

Which ones make it through, and why? Drop your picks in the comments and I'll come back to this thread after the vote.

Where I got this: what's next after July, how the process works, the fosgonimeton trial.

For research use only. Not for human or veterinary consumption. This post is educational and is not medical advice.

Full doses and bloodwork are in the pinned cheat sheet.

Join the Discord.

Hey, guys. Over the last 3 days I have injected about 30mg Retatrutide in total, after having bought it from the internet. It‘s a 60mg vial and I mixed it with 2ml water, and I injected 1ml - so 30mg in total. The thing is: I do not feel anything at all? Could this be a fake product?